Nextcure’s Society for Immunotherapy of Cancer presentation gave investors little reason for cheer, but there's better news for Pieris, Celyad and Nektar.
Axsome hopes to find a niche with its migraine project, AXS-07, while Kala's latest phase III needs to win over the regulators.
Celgene’s registrational Transcend NHL-001 study will be a big story at Ash, but the early focus falls on what has not been presented.
The period between a device company’s foundation and its acquisition has lengthened over the past few years, and currently stands at more than a decade.
The orthopaedics sector has seen several sizeable mergers over the past decade. Might it see more?
Amarin’s Vascepa is widely expected to receive approval in a huge new patient population. So why has the company not been bought?
The first clinical data from Rubius Therapeutics will show whether its lead project, RTX-134, has a future. More importantly, the readout is a test of its entire red…
Iterum should soon find out if it has an approvable asset in the antibiotic sulopenem, but even if the group succeeds it still has a hard road ahead.
The group has the only approved cell-based cancer blood test in the world, but competing in an increasingly cutthroat market will be tough.
Orphan status for its haemophilia cell therapy and buy-in from Lilly on its diabetes project are good signs for Sigilon, but research is still very early.
CMR Surgical’s private round is the largest ever venture deal for a European medtech. And the point is to get to profitability, not flotation.